The attacks come after state and local ransomware attacks in New York, Louisiana, Maryland and Florida resulted in the loss of significant sums.Technologyread more
China's pursuit of the Middle East may spur growth in the Islamic finance sector.World Economyread more
Twitter and Facebook have suspended accounts believed to be tied to a state-backed disinformation campaign originating from inside China.Technologyread more
United States Steel Corp will temporarily lay off hundreds of workers at its Great Lakes facility in Michigan in coming weeks, according to a filing the steelmaker made with...US Marketsread more
The report comes as Trump in recent days has lashed out over media reports about growing recession fears.Politicsread more
Beijing will lower borrowing costs for companies, but that may not boost the economy as much as some hope.China Economyread more
Stocks are bouncing higher but could be trapped in a range longer term, until there's a resolution of the trade wars.Market Insiderread more
Stocks in Asia mostly traded higher Tuesday morning as minutes from the Reserve Bank of Australia's July meeting were released. The People's Bank of China also published its...Asia Marketsread more
Powell will have the opportunity if not to walk back the "midcycle" assessment then to at least provide some further explanation about what it means.Economyread more
Apple has spent more than $6 billion on original TV shows and movies for its forthcoming Apple TV+ service, according to a Financial Times report on Monday.Technologyread more
The Business Roundtable, led by Jamie Dimon, gives a new definition of the "purpose of a corporation."Marketsread more
Eli Lilly on Thursday said the U.S. Food and Drug Administration approved its migraine drug Emgality, marking the third approval from a promising new class of treatments for the often debilitating headaches.
Lilly said it plans to sell the drug, known chemically as galcanezumab, at a list price of $6,900 a year, or $575 month. That is identical to the list prices for the other new migraine treatments, Aimovig from Amgen and Novartis, and Teva Pharmaceutical's Ajovy.
The three medicines, most commonly administered as monthly self-injections, belong to a class of biotech drugs known as CGRP inhibitors that block a protein involved in setting off migraines. CGRP, or calcitonin gene-related peptide, is believed to be involved in the migraine process, such as dilation of blood vessels in the brain.
Around 39 million Americans suffer from migraine headaches, according to the Migraine Research Foundation. Migraines can cause intense pain, nausea and sensitivity to light and sounds, severely disrupting the ability to work or function.
Prior migraine treatments are mostly repurposed generic drugs, including anti-depressants and hypertension medicines, or are medicines that cause nausea and other adverse side effects. Allergan's anti-wrinkle injection Botox is approved for patients suffering from 15 or more migraine headaches a month.
Aimovig become the first CGRP inhibitor to launch, after receiving U.S. approval in May. Early demand for Aimovig has been strong, buoyed in part by Amgen programs giving patients two months of free samples followed by up to a year's supply of the drug for those having trouble with insurance coverage.
Lilly said it plans to launch a similar program that would allow commercially insured patients to receive up to 12 months of Emgality at no cost to the patient.
Lilly said it is in late-stage discussions with the top four or five U.S. health insurers and pharmacy benefit managers with the aim having the drug covered as widely as possible. Those include negotiations around rebates and discounts off the list price.
The talks also include potential value-based payment models, which would allow employers and insurers to reclaim some money if the drug is not effective for a patient, Lilly said.
The company said it expects to begin shipping the drug very soon after approval.